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Bacterial outer membrane vesicles (OMVs) are non-infectious but highly immunogenic particles. These vesicles 
are used as vaccines against the disease of the source bacteria. Fascinatingly, the addition of heterologous 
antigens to these vesicles creates a versatile vaccine platform. Such a platform can be used as an alternative to 
subunit vaccines, during infectious disease outbreaks or for the development of vaccines against pathogens that 
require high containment. A unique aspect of this platform is the reusability of the production process for many 
different vaccines. This in turn could reduce the time to market for new vaccines significantly. We designed a 
heterologous OMV vaccine concept for Lyme disease based on spontaneous released OMVs from Neisseria 
meningitidis that express the Outer surface protein A (OspA) of Borrelia burgdorferi on the surface. The 
productivity of spontaneously released OMVs was improved by the introduction of oxidative stress to the 
bacterial culture. Increased dissolved oxygen concentrations during cultivation showed to be an excellent 
process parameter for enhanced release of OMVs, while the bacterial culture remains viable. This presentation 
will cover the development of the OMV-based vaccine platform and the impact of changes in the upstream 























Figure 1 – Heterologous antigens on outer membrane vesicles as vaccine platform 
